The expression levels and clinical significance of MFG-E8 and CD133 in epithelial ovarian cancer

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
   PubMed Web of Science ®Google Scholar
• Neniskyte U, Brown GC. Lactadherin/MFG-E8 is essential for microglia-mediated neuronal loss and phagoptosis induced by amyloid β. J Neurochem. 2013;126(3):312–317.
   PubMed Web of Science ®Google Scholar
• Bu HF, Zuo XL, Wang X, et al. Milk fat globule-EGF factor 8/lactadherin plays a crucial role in maintenance and repair of murine intestinal epithelium. J Clin Invest. 2007;117(12):3673–3683.
   PubMed Web of Science ®Google Scholar
• Wang M, Fu Z, Wu J, et al. MFG-E8 activates proliferation of vascular smooth muscle cells via integrin signaling. Aging Cell. 2012;11(3):500–508.
   PubMed Web of Science ®Google Scholar
• Silvestre JS, Thery C, Hamard G, et al. Lactadherin promotes VEGF-dependent neovascularization. Nat Med. 2005;11(5):499–506.
   PubMed Web of Science ®Google Scholar
• Kanemura T, Miyata H, Makino T, et al. Immunoregulatory influence of abundant MFG-E8 expression by esophageal cancer treated with chemotherapy. Cancer Sci. 2018;109(11):3393–3402.
   PubMed Web of Science ®Google Scholar
• Huang Y, Prasad M, Lemon WJ, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA. 2001;98(26):15044–15049.
   PubMed Web of Science ®Google Scholar
• Oba J, Moroi Y, Nakahara T, et al. Expression of milk fat globule epidermal growth factor-VIII may be an indicator of poor prognosis in malignant melanoma. Br J Dermatol. 2011;165(3):506–512.
   PubMed Web of Science ®Google Scholar
• Jinushi M, Nakazaki Y, Carrasco DR, et al. Milkfat globule EGF-8 promotes melanoma progression through coordinated Akt and twist signaling in the tumor microenvironment. Cancer Res. 2008;68(21):8889–8898.
   PubMed Web of Science ®Google Scholar
• Takahashi S, Kamiyama T, Tomaru U, et al. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep. 2010;24:1201–1212.
   PubMed Web of Science ®Google Scholar
• Zhao P, Lu Y, Jiang X, et al. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci. 2011;102(5):1107–1111.
   PubMed Web of Science ®Google Scholar
• Pallini R, Ricci-Vitiani L, Montano N, et al. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer. 2011;117(1):162–174.
   PubMed Web of Science ®Google Scholar
• Baba T, Convery PA, Matsumura N, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 2009;28(2):209–218.
   PubMed Web of Science ®Google Scholar
• Scully RE. World health organization classification and nomenclature of ovarian cancer. Natl Cancer Inst Monogr. 1975;42:5–7.
   PubMedGoogle Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer . 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Sasaki A, Kamiyama T, Yokoo H, et al. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep. 2010;24(2):537–546.
   PubMed Web of Science ®Google Scholar
• Shimada M, Sugimoto K, Iwahashi S, et al. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol. 2010;45(8):896–902.
   PubMed Web of Science ®Google Scholar
• Yang C, Hayashida T, Forster N, et al. The integrinαvβ3-5 ligand MFG-E8 is a p63/p73 target gene in triple-negative breast cancers but exhibits suppressive functions in ER (+) and erbB2 (+) breast cancers. Cancer Res. 2011;71(3):937–945.
   PubMed Web of Science ®Google Scholar
• Ben D, Helene TS, Arild H, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med. 2011;15:535–544.
   PubMed Web of Science ®Google Scholar
• Buchholz M, Braun M, Heidenblut A, et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene. 2005;24(44):6626–6636.
   PubMed Web of Science ®Google Scholar
• Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006;9(4):287–300.
   PubMed Web of Science ®Google Scholar
• Tibaldi L, Leyman S, Nicolas A, et al. New blocking antibodies impede adhesion, migration and survival of ovarian cancer cells, highlighting MFGE8 as a potential therapeutic target of human ovarian carcinoma. PLoS One. 2013;8(8):e72708.
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo WJ, Liao MJ, et al. The epithelial- mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133(4):704–715.
   PubMed Web of Science ®Google Scholar
• Zhang J, Guo X, Chang DY, et al. CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol. 2012;25(3):456–464.
   PubMed Web of Science ®Google Scholar
• Jinushi M, Sato M, Kanamoto A, et al. Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms. J Exp Med. 2009;206(6):1317–1326.
   PubMed Web of Science ®Google Scholar
• Jinushi M, Chiba S, Yoshiyama H, et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci USA. 2011;108(30):12425–12430.
   PubMed Web of Science ®Google Scholar
• Jinushi M, Baghdadi M, Chiba S, et al. Regulation of cancer stem cell activities by tumor-associated macrophages. Am J Cancer Res. 2012;2(5):529–539.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Rudaitis V, Zvirblis T, Kanopiene D, et al. BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III–IV) ovarian cancer. Int J Gynecol Cancer. 2014;24(8):1395–1400.
   PubMed Web of Science ®Google Scholar
• Page CL, Rahimi K, Kobel M, et al. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. BMC Cancer. 2018;18(1):347.
   PubMedGoogle Scholar